

Poster session 4 Friday 7-9 AM

- P4-03-01** Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers  
*Dixon JM, Turnbull AK, Tanioka M, Wheless A, Garrett A, Martinez-Perez C, Parker J, He X, Sims AH, Thomas JS, Carey LA, Perou CM.*
- P4-03-12** Effects of PI3K inhibitors on endocrine-resistant cell lines and differences in the characteristics of ER positive breast cancer cells after acquired resistance to the inhibitors  
*Tokuda E, Komatsu T, Sasaki S, Tsuboi K, Nakamura M, Iida M, Niwa T, Saito M, Hayashi S-I.*
- P4-03-13** Combined estrogen receptor alpha and XPO1 targeting to overcome endocrine resistance  
*Madak Erdogan Z, Kulkoyluoglu E.*
- P4-04-03** Hyperactive FOXA1 activates super-enhancer-engaged HIF2 $\alpha$ /EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer  
*Fu X, Pereira R, De Angelis C, Veeraraghavan J, Shea MJ, Nanda S, Feng Q, Jeselsohn R, O'Malley BW, Brown M, Osborne CK, Schiff R*
- P4-04-08** Therapeutic strategy for ER $\alpha$  mutation driven-endocrine resistance in ER-positive breast cancers  
*Kim J-A, Fuqua SAW.*
- P4-04-12** Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer  
*Lim E, Portman N, Alexandrou S, Haupt S, Haupt Y, Caldon E*
- P4-10-04** EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer  
*Hughes ME, Frank ES, Merrill MS, Santiago RA, Kuhnly N, Crowley LM, Gupta G, Winer EP, Lin NU.*
- P4-10-05** Engaging linguistically and ethnically diverse low income women in health research: A randomized controlled trial  
*Joseph G, Nickell A, Cohen E, Burke NJ, Colen S, Lawlor K, Guerra C, Stewart SL.*
- P4-10-07** Patient-centered initiatives for improving trial participation of diverse patient populations in the open-label phase 3b compLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2- advanced breast cancer  
*Small T, Marsano-Feeley J, Fernandez A, Grasso T, Feldman K, Petrone S, Bugazia N, Wong C, Meyer J, Schutta K, Purkayastha D, Saintil K, Spatz Caplan E, Waltman-Johnson K.*
- P4-12-08** Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis  
*Raphael J, Helou J, Naimark DM.*